Dexpramipexole is ineffective in two models of ALS related neurodegeneration.

Treatment options for people living with amyotrophic lateral sclerosis (ALS) are limited and ineffective. Recently, dexpramipexole (RPPX) was advanced into human ALS clinical trials. In the current studies, we investigated RPPX in two parallel screening systems: 1) appropriately powered, sibling-mat...

詳細記述

書誌詳細

出版年:	PLoS ONE
主要な著者:	Fernando G Vieira, Eva LaDow, Andy Moreno, Joshua D Kidd, Beth Levine, Kenneth Thompson, Alan Gill, Steven Finkbeiner, Steven Perrin
フォーマット:	論文
言語:	英語
出版事項:	Public Library of Science (PLoS) 2014-01-01
オンライン･アクセス:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0091608&type=printable